Alexion Pharmaceuticals Inc. Release: Longer-Term Data on Soliris Showed Significant and Sustained Benefits for Patients with aHUS

CHESHIRE, Conn.--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today presented longer-term data from the extensions of two pivotal phase 2 studies of SolirisĀ® (eculizumab) in patients with atypical hemolytic uremic syndrome (aHUS): (i) a study in patients with a long duration of disease prior to receiving intervention with Soliris following chronic plasma exchange/infusion (PE/PI) and (ii) a study in patients with a shorter duration of disease prior to intervention with Soliris who had progressive clinical complications despite intensive PE/PI. Results demonstrated that ongoing treatment with Soliris sustained the suppression of complement-mediated thrombotic microangiopathy (TMA), maintained or further improved longer-term renal function, and enhanced quality of life. These data were presented at the annual meeting of the American Society of Nephrology (ASN) in Philadelphia.

Back to news